235 related articles for article (PubMed ID: 19417098)
1. Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke.
Protasi F; Paolini C; Dainese M
J Physiol; 2009 Jul; 587(Pt 13):3095-100. PubMed ID: 19417098
[TBL] [Abstract][Full Text] [Related]
2. Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice.
Dainese M; Quarta M; Lyfenko AD; Paolini C; Canato M; Reggiani C; Dirksen RT; Protasi F
FASEB J; 2009 Jun; 23(6):1710-20. PubMed ID: 19237502
[TBL] [Abstract][Full Text] [Related]
3. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia.
Michelucci A; Paolini C; Boncompagni S; Canato M; Reggiani C; Protasi F
FASEB J; 2017 Aug; 31(8):3649-3662. PubMed ID: 28465322
[TBL] [Abstract][Full Text] [Related]
4. Lessons from calsequestrin-1 ablation in vivo: much more than a Ca(2+) buffer after all.
Protasi F; Paolini C; Canato M; Reggiani C; Quarta M
J Muscle Res Cell Motil; 2011 Dec; 32(4-5):257-70. PubMed ID: 22130610
[TBL] [Abstract][Full Text] [Related]
5. Functional Calsequestrin-1 Is Expressed in the Heart and Its Deficiency Is Causally Related to Malignant Hyperthermia-Like Arrhythmia.
Sun Z; Wang L; Han L; Wang Y; Zhou Y; Li Q; Wu Y; Talabieke S; Hou Y; Wu L; Liu R; Fu Z; You H; Li BY; Zheng Y; Luo D
Circulation; 2021 Sep; 144(10):788-804. PubMed ID: 34162222
[TBL] [Abstract][Full Text] [Related]
6. CASQ1 gene is an unlikely candidate for malignant hyperthermia susceptibility in the North American population.
Kraeva N; Zvaritch E; Frodis W; Sizova O; Kraev A; MacLennan DH; Riazi S
Anesthesiology; 2013 Feb; 118(2):344-9. PubMed ID: 23460944
[TBL] [Abstract][Full Text] [Related]
7. Oxygen Consumption and Basal Metabolic Rate as Markers of Susceptibility to Malignant Hyperthermia and Heat Stroke.
Serano M; Pietrangelo L; Paolini C; Guarnier FA; Protasi F
Cells; 2022 Aug; 11(16):. PubMed ID: 36010545
[TBL] [Abstract][Full Text] [Related]
8. Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia in an Athlete: Evidence for a Link?
Poussel M; Guerci P; Kaminsky P; Heymonet M; Roux-Buisson N; Faure J; Fronzaroli E; Chenuel B
J Athl Train; 2015 Nov; 50(11):1212-4. PubMed ID: 26565425
[TBL] [Abstract][Full Text] [Related]
9. Ablation of Calsequestrin-1, Ca
Protasi F; Girolami B; Serano M; Pietrangelo L; Paolini C
Front Physiol; 2022; 13():1033300. PubMed ID: 36311237
[No Abstract] [Full Text] [Related]
10. Malignant hyperthermia, environmental heat stress, and intracellular calcium dysregulation in a mouse model expressing the p.G2435R variant of RYR1.
Lopez JR; Kaura V; Diggle CP; Hopkins PM; Allen PD
Br J Anaesth; 2018 Oct; 121(4):953-961. PubMed ID: 30236258
[TBL] [Abstract][Full Text] [Related]
11. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
[TBL] [Abstract][Full Text] [Related]
12. On the nature of the link between malignant hyperthermia and exertional heatstroke.
Bourdon L; Canini F
Med Hypotheses; 1995 Sep; 45(3):268-70. PubMed ID: 8569550
[TBL] [Abstract][Full Text] [Related]
13. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
[TBL] [Abstract][Full Text] [Related]
14. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
[TBL] [Abstract][Full Text] [Related]
15. Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
Eltit JM; Bannister RA; Moua O; Altamirano F; Hopkins PM; Pessah IN; Molinski TF; López JR; Beam KG; Allen PD
Proc Natl Acad Sci U S A; 2012 May; 109(20):7923-8. PubMed ID: 22547813
[TBL] [Abstract][Full Text] [Related]
16. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
17. Ryanodine receptor type 1 (RyR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by non-coplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95).
Ta TA; Pessah IN
Neurotoxicology; 2007 Jul; 28(4):770-9. PubMed ID: 17023049
[TBL] [Abstract][Full Text] [Related]
18. [Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex].
Lunardi J; Monnier N
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S70-7. PubMed ID: 15269663
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effects of novel type1 ryanodine receptor inhibitor on skeletal muscle diseases].
Yamazawa T; Kobayashi T; Kurebayashi N; Murayama T
Nihon Yakurigaku Zasshi; 2022; 157(1):15-22. PubMed ID: 34980804
[TBL] [Abstract][Full Text] [Related]
20. The disorders of the calcium release unit of skeletal muscles: what have we learned from mouse models?
Canato M; Capitanio P; Reggiani C; Cancellara L
J Muscle Res Cell Motil; 2015 Feb; 36(1):61-9. PubMed ID: 25424378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
